ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI) (ISDC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02819700
Recruitment Status : Unknown
Verified June 2016 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was:  Recruiting
First Posted : June 30, 2016
Last Update Posted : June 30, 2016
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:
Behavioural disorders are very common right from the initial stage of dementia and contribute to loss of autonomy. Behavioural dysexecutive disorders have a particular status due to their prevalence and their diagnostic importance, as they often constitute the initial symptoms of Frontotemporal Dementia (FTD), Semantic Dementia (SD) and Huntington's disease (HD) and they are classically more frequent in vascular dementia (VaD) than in Alzheimer's disease (AD). The presence of these disorders at the stage of Mild Cognitive Impairment (MCI) has only been partially evaluated and would increase the risk of progression to dementia. These classical data are based on non-standardized assessments and non-validated diagnostic criteria. The Groupe de Reflexion pour l'Evaluation des Fonctions EXécutives (GREFEX) has developed a standardized assessment tool for behavioural dysexecutive disorders, the Behavioural Dysexecutive Syndrome Inventory (BDSI) and has validated diagnostic criteria for this syndrome.

Condition or disease Intervention/treatment
Frontotemporal Dementia Huntington Disease Alzheimer Disease Semantic Dementia Dementia, Vascular Behavioral: prevalence of behavioural dysexecutive syndrome

Study Type : Observational
Estimated Enrollment : 285 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
Study Start Date : January 2013
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017



Intervention Details:
  • Behavioral: prevalence of behavioural dysexecutive syndrome
    Behavioural Dysexecutive Syndrome Inventory (ISDC)


Primary Outcome Measures :
  1. ISDC (Behavioural Dysexecutive Syndrome Inventory) [ Time Frame: Day 0 ]
    Behavioural Dysexecutive Syndrome Inventory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
French-speaking subjects between the ages of 40 and 85 years with an MMSE score > 15/30, followed for AD or MCI or VaD or FTD or SD or HD will be selected by their neurologist during a routine memory assessment visit.
Criteria

Inclusion Criteria:

  • Support to the consultation memory for a neurological disease ( frontotemporal dementia , vascular dementia , Alzheimer's disease , mild cognitive disorder, Huntington's disease ( with genetic diagnosis confirmed : number of CAG triplets > 36 symptomatic : UHDRS score ≥5 ) with MMS > 15
  • Age 40 to 85 years
  • French
  • Informing reliable
  • Agreeing to participate in the study.

Exclusion Criteria:

  • Presence of other disease disturbing behavior ( current depressive syndrome , schizophrenia, psychosis , past psychiatric disorders requiring a stay > 2 days in a specialized environment ) or cognition (mental retardation , illiteracy , respiratory failure, kidney , liver , heart ) or preventing the realization of the tests ( perceptual or motor deficit ) intrecérébrale pacing therapy or stem cell transplant , patient protected ( under supervision or guardianship ) , pregnant and / or breastfeeding and lack of consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819700


Contacts
Contact: Olivier GODEFROY, MD, PhD +33 3 22 66 84 47 godefroy.olivier@chu-amiens.fr

Locations
France
CHU Amiens Recruiting
Amiens, France, 80054
Contact: Olivier GODEFROY, MD, PhD    +33 3 22 66 84 47    godefroy.olivier@chu-amiens.fr   
CHU Strasbourg Not yet recruiting
Strasbourg, France, 67091
Contact: Frédéric BLANC, MD, PhD         
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Investigators
Principal Investigator: Olivier GODEFROY, MD, PhD CHU Amiens

Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT02819700     History of Changes
Other Study ID Numbers: PI11-PR-GODEFROY-2
First Posted: June 30, 2016    Key Record Dates
Last Update Posted: June 30, 2016
Last Verified: June 2016

Keywords provided by Centre Hospitalier Universitaire, Amiens:
behavioural disorders

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Huntington Disease
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Dementia, Vascular
Mental Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Basal Ganglia Diseases
Chorea
Dyskinesias
Movement Disorders
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Cognition Disorders
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Aphasia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations